Incentives are an effective adjunct to standard therapy for opiate-, marijuana-, alcohol-, and cocaine-addicted patients. Patients in most of those early studies always received vouchers exchangeable for goods or services, rather than chances to win prizes, for positive behaviors; costs typically ran to about $1,000 per patient over 3 months, with the result that few community programs adopted the motivational incentive approach. Dr. Petry developed her prize-drawing system to make incentives affordable for community programs. She has tested it successfully in several Connecticut treatment programs, and now its effectiveness is confirmed by the CTN trial. NIDA is collaborating with the Substance Abuse and Mental Health Services Administration’s Addiction Technology Transfer Center to promote awareness of the low-cost motivational incentive technique (see textbox, page 6).

The CTN researchers note that some community-based treatment providers resist the idea of motivational incentives based on a belief that clinicians should not reward patients for behaviors “that they are supposed to do anyway.” In response, the researchers point out that groups and individuals often use external incentives to motivate others—from employees’ bonuses to children’s allowances for household chores. Dr. Stitzer advocates a shift in perspective from punishing lapses to celebrating successes. She observes that counselors have often changed their views when they have seen incentives help revolving-door patients stay in therapy. “Incentive programs—the idea of catching people being good and rewarding the behavior—can infuse addiction treatment with a positive outlook and reinvigorate patients and counselors,” says Dr. Stitzer.

Source

Buprenorphine Plus Behavioral Therapy Is Effective For Adolescents With Opioid Addiction

A new study looks at extending the role of buprenorphine for treatment of adolescents.

By Patrick Zickler, NIDA Notes Contributing Writer

Adolescents addicted to opioids responded better to buprenorphine than clonidine in a clinical trial in which all patients also received behavioral therapy. In the NIDA-supported comparison trial at the University of Vermont, adolescents who received buprenorphine attended more scheduled counseling sessions than peers who received clonidine and had higher rates of successful induction to a relapse prevention regimen of naltrexone. The study, led by Dr. Lisa Marsch, is the first published randomized controlled study of treatments for adolescents addicted to opioids.

“Heroin abuse among American teens has doubled over the past decade, and abuse of prescription opioids such as OxyContin and Vicodin has increased even more,” says Dr. Marsch. “In light of those figures, it’s important to have a scientific basis for selecting treatments for opioid-dependent teens. We know from previous research and clinical experience that buprenorphine and, to a lesser extent, clonidine are among the medications that have been shown to be effective for treating opioid-addicted adults, but we haven’t known how helpful they can be for adolescents.”

Dr. Marsch and colleagues enrolled 36 opioid-addicted adolescents, aged 13 to 18, in a 28-day outpatient treatment program. Half the participants (9 male, 9 female) received buprenorphine in tablet form, the

Buprenorphine Detoxification Sets Stage For Recovery

Buprenorphine and clonidine were compared in a randomized controlled trial with adolescents addicted to opioids who were enrolled in an 8-week treatment program. Adolescents who received buprenorphine were more likely to complete the study and less likely to relapse. Those receiving clonidine had higher rates of successful induction to a relapse prevention regimen of naltrexone.

Source
rest (5 male, 13 female) clonidine via transdermal patch; each patient also was given a placebo resembling the other treatment. Medication dosages varied depending on each participant’s weight and the amount of drug he or she reported abusing before beginning treatment; dosages of buprenorphine were in the low to moderate range of those typically given to opioid-addicted adults.

All participants also received behavioral therapy based on the Community Reinforcement Approach: three 1-hour sessions each week of counseling on methods to minimize involvement in situations that might lead to drug-taking, training to help recognize and control urges to abuse opioids, and encouragement to recruit family members as allies for abstinence. Participants earned vouchers worth $2.50 for the first opioid-negative urine sample, plus an additional $1.25 for each subsequent one, and a $10 bonus for each set of three consecutive negative samples. Continuous abstinence could earn participants $152.50 in vouchers redeemable for rewards such as ski passes, CDs, gym passes, and clothing.

Buprenorphine and clonidine both supported high rates of abstinence. Among participants who completed treatment, rates were 78 percent and 81 percent, respectively, confirmed by urine samples provided at the thrice-weekly sessions. However, nearly twice as many buprenorphine as clonidine recipients completed the 4-week treatment (72 percent compared with 39 percent). “The high rate of retention in the buprenorphine group is particularly noteworthy,” Dr. Marsch says, “because long-term success in recovery is directly related to the amount of time patients spend in treatment.” And, she adds, the willingness of most patients who received buprenorphine to continue treatment with naltrexone following completion of the 28-day program is similarly encouraging. Sixty-one percent of the buprenorphine group, but only 5 percent of those who received clonidine accepted naltrexone.

“Dr. Marsch’s research is an important first step in systematically studying adolescents who are addicted to opioids,” says Dr. Ivan Montoya of NIDA’s Division of Pharmacotherapies and Medical Consequences of Drug Abuse. “We know that there are differences in the patterns of opioid abuse and addiction in young people compared with adults. We need dedicated studies like this one to understand how teens are affected by opiate drugs and how best to treat them.”

The next step in Dr. Marsch’s research will involve a larger sample of young opioid abusers. “We want to evaluate buprenorphine’s effectiveness if treatment is extended to 2 months rather than 28 days,” she says. “We will also examine the most effective doses and dosing regimens for various subgroups of young patients.”

S O U R C E
Low-Cost Incentives Improve Outcomes in Stimulant Abuse Treatment

In community-based treatment programs, the intervention added $2.42 per patient per day to counseling costs.

BY LORI WHITTEN,
NIDA Notes Staff Writer

The opportunity to win rewards worth as little as $1 for abstinence can help motivate outpatients to stay in behavioral therapy and remain drug-free, according to a NIDA Clinical Trials Network (CTN) study. At eight community-based addiction treatment programs across the United States, stimulant abusers who could earn a chance to win a prize by providing drug-free urine samples were four times as likely as peers who were not offered this incentive to attain 12 weeks of continuous abstinence. Prizes for the incentive intervention cost the programs about $200, or $2.42 a day per participant.

"Many addiction treatment clinics face the challenge of high patient dropout rates. Reinforcing abstinence helps keep patients interested in attending treatment for longer periods, which can facilitate behavioral changes to keep them off drugs for the long haul," says Dr. Nancy Petry of the University of Connecticut School of Medicine, coleader of the study. Prior research has found that, no matter how it is achieved, duration of abstinence during treatment is one of the best predictors of abstinence 1 year later. "More patients achieve this therapeutic milestone with a boost from incentive programs," says the study's other coleader, Dr. Maxine Stitzer of The Johns Hopkins University School of Medicine.

The CTN investigators randomly assigned 415 treatment-seeking stimulant abusers (see chart) to one of two conditions: usual care or usual care plus abstinence-based incentives for 12 weeks. Usual care typically consisted of group counseling, although some patients received individual and family therapy. Patients gave urine and breath samples twice weekly. Research assistants tested the urine samples for stimulants, opiates, and marijuana, and tested the breath samples for alcohol.

CHARACTERISTICS OF STUDY PARTICIPANTS

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>52</td>
</tr>
<tr>
<td>African American</td>
<td>35</td>
</tr>
<tr>
<td>Hispanic</td>
<td>12</td>
</tr>
<tr>
<td>Other</td>
<td>7</td>
</tr>
<tr>
<td>Male</td>
<td>44</td>
</tr>
<tr>
<td>Unemployed</td>
<td>68</td>
</tr>
<tr>
<td>On parole or probation</td>
<td>25</td>
</tr>
<tr>
<td>Abuse of other drugs</td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>42</td>
</tr>
<tr>
<td>Marijuana</td>
<td>20</td>
</tr>
<tr>
<td>Opioids</td>
<td>9</td>
</tr>
</tbody>
</table>

Research in Brief

1. Office-Based Buprenorphine
2. Steroid Abuse is a High-Risk Route to the Finish Line
3. Ethnicity Influences Early Smoking
4. Buprenorphine Plus Behavioral Therapy Is Effective for Adolescents With Opioid Addiction
5. Brain Mechanism Turns Off Cocaine-Related Memory in Rats
6. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
7. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
8. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
9. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
10. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
11. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
12. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
13. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
14. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
15. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
16. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
17. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
18. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
19. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
20. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
21. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
22. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
23. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
24. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
25. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
26. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
27. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
28. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
29. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
30. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
31. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
32. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
33. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
34. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
35. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
36. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
37. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
38. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
39. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
40. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
41. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
42. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
43. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
44. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
45. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
46. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
47. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
48. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
49. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
50. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
51. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
52. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
53. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
54. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
55. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
56. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
57. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
58. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
59. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
60. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
61. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
62. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
63. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
64. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
65. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
66. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
67. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
68. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
69. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
70. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
71. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
72. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
73. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
74. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
75. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
76. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
77. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
78. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
79. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
80. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
81. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
82. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
83. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
84. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
85. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
86. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
87. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
88. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
89. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
90. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
91. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
92. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
93. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
94. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
95. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
96. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
97. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
98. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
99. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
100. Marijuana Smoking Is Associated With a Spectrum of Respiratory Disorders
High School Seniors Steadily Increase Nonmedical Use of Sedatives Over 15 Years

The annual Monitoring the Future Survey identified a disturbing pattern in the nonmedical use of sedatives, including barbiturates, among 12th graders: The overall prevalence has risen steadily since 1992, and now stands at 7.2 percent.
In this article, the author describes a study which looks at extending the role of buprenorphine for the treatment of opioid-addicted adolescents. The study involved 36 opioid-addicted adolescents, aged 13 to 18, in a 28-day outpatient treatment program. Half the participants received buprenorphine; the other half received clonidine, another treatment medication. All participants also received behavioral therapy based on the Community Reinforcement Approach. While both buprenorphine and clonidine proved effective in supporting abstinence, nearly twice as many youth who received buprenorphine as clonidine completed the 4-week treatment. This is significant because long-term success in recovery is directly related to the amount of time patients spend in treatment. The researchers' next steps will be to examine the most effective doses and dosing regimens for various subgroups of young patients.
In this article, the author describes a study which looks at extending the role of buprenorphine for the treatment of opioid-addicted adolescents. The study involved 36 opioid-addicted adolescents, aged 13 to 18, in a 28-day outpatient treatment program. Half the participants received buprenorphine; the other half received clonidine, another treatment medication. All participants also received behavioral therapy based on the Community Reinforcement Approach. While both buprenorphine and clonidine proved effective in supporting abstinence, nearly twice as many youth who received buprenorphine as clonidine completed the 4-week treatment. This is significant because long-term success in recovery is directly related to the amount of time patients spend in treatment. The researchers' next steps will be to examine the most effective doses and dosing regimens for various subgroups of young patients.